 SAN DIEGO, March 16, 2021 PRNewswire -- Evofem Biosciences, Inc., NASDAQ: EVFM today announced publication of the pivotal manuscript from the AMPREVENCE clinical trial in the highly respected American Journal of Obstetrics and Gynecology AJOG. This double-blinded, placebo-controlled, multicenter study of EVO100 met its primary and secondary efficacy endpoints with statistically significant reductions in the risk of chlamydia and gonorrhea infections in women at high risk of infection. 